Skip to main content
Top
Published in: Clinical and Experimental Nephrology 7/2021

01-07-2021 | Nephrectomy | Original article

Involvement of necroptosis in contrast-induced nephropathy in a rat CKD model

Authors: Satoru Shibata, Norihito Moniwa, Atsushi Kuno, Ayumu Kimura, Wataru Ohwada, Hirohito Sugawara, Yufu Gocho, Marenao Tanaka, Toshiyuki Yano, Masato Furuhashi, Masaya Tanno, Takayuki Miki, Tetsuji Miura

Published in: Clinical and Experimental Nephrology | Issue 7/2021

Login to get access

Abstract

Background

The risk of contrast-induced nephropathy (CIN) is high in patients with chronic kidney disease (CKD). However, the mechanism of CIN in CKD is not fully understood. Here, we prepared a clinically relevant model of CIN and examined the role of necroptosis, which potentially cross-talks with autophagy, in CIN.

Methods

In Sprague–Dawley rats, CKD was induced by subtotal nephrectomy (SNx, 5/6 nephrectomy) 4 weeks before induction of CIN. CIN was induced by administration of a contrast medium (CM), iohexol, following administration of indomethacin and N-omega-Nitro-l-arginine methyl ester. Renal function and tissue injuries were assessed 48 h after CM injection.

Results

Serum creatinine (s-Cre) and BUN were increased from 0.28 ± 0.01 to 0.52 ± 0.02 mg/dl and from 15.1 ± 0.7 to 29.2 ± 1.2 mg/dl, respectively, after SNx alone. CM further increased s-Cre and BUN to 0.69 ± 0.03 and 37.2 ± 2.1, respectively. In the renal tissue after CM injection, protein levels of receptor-interacting serine/threonine-protein kinase (RIP) 1, RIP3, cleaved caspase 3, and caspase 8 were increased by 64 ~ 212%, while there was reduction in LC3-II and accumulation of p62. Necrostatin-1, an RIP1 inhibitor, administered before and 24 h after CM injection significantly suppressed elevation of s-Cre, BUN and urinary albumin levels, kidney injury molecule-1 expression and infiltration of CD68-positive macrophages in renal tissues after CM injection.

Conclusion

The results suggest that necroptosis of proximal tubular cells contributes to CIN in CKD and that suppression of protective autophagy by pro-necroptotic signaling may also be involved.
Appendix
Available only for authorised users
Literature
1.
go back to reference James MT, Samuel SM, Manning MA, Tonelli M, Ghali WA, Faris P, et al. Contrast-induced acute kidney injury and risk of adverse clinical outcomes after coronary angiography: a systematic review and meta-analysis. Circ Cardiovasc Interv. 2013;6:37–43.CrossRef James MT, Samuel SM, Manning MA, Tonelli M, Ghali WA, Faris P, et al. Contrast-induced acute kidney injury and risk of adverse clinical outcomes after coronary angiography: a systematic review and meta-analysis. Circ Cardiovasc Interv. 2013;6:37–43.CrossRef
2.
go back to reference Azzalini L, Spagnoli V, Ly HQ. Contrast-induced nephropathy: from pathophysiology to preventive strategies. Can J Cardiol. 2016;32:247–55.CrossRef Azzalini L, Spagnoli V, Ly HQ. Contrast-induced nephropathy: from pathophysiology to preventive strategies. Can J Cardiol. 2016;32:247–55.CrossRef
3.
go back to reference Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: Development and initial validation. J Am Col Cardiol. 2004;44:1393–9. Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: Development and initial validation. J Am Col Cardiol. 2004;44:1393–9.
4.
go back to reference Heyman SN, Rosen S, Rosenberger C. Renal parenchymal hypoxia, hypoxia adaptation, and the pathogenesis of radiocontrast nephropathy. Clin J Am Soc Nephrol. 2008;3:288–96.CrossRef Heyman SN, Rosen S, Rosenberger C. Renal parenchymal hypoxia, hypoxia adaptation, and the pathogenesis of radiocontrast nephropathy. Clin J Am Soc Nephrol. 2008;3:288–96.CrossRef
5.
go back to reference Mehran R, Dangas GD, Weisbord SD. Contrast-associated acute kidney injury. N Engl J Med. 2019;380:2146–55.CrossRef Mehran R, Dangas GD, Weisbord SD. Contrast-associated acute kidney injury. N Engl J Med. 2019;380:2146–55.CrossRef
6.
go back to reference Tumlin J, Stacul F, Adam A, Becker CR, Davidson C, Lameire N, et al. Pathophysiology of contrast-induced nephropathy. Am J Cardiol. 2006;98:14K-20K.CrossRef Tumlin J, Stacul F, Adam A, Becker CR, Davidson C, Lameire N, et al. Pathophysiology of contrast-induced nephropathy. Am J Cardiol. 2006;98:14K-20K.CrossRef
7.
go back to reference Quintavalle C, Brenca M, de Micco F, Fiore D, Romano S, Romano MF, et al. In vivo and in vitro assessment of pathways involved in contrast media-induced renal cells apoptosis. Cell Death Dis. 2011;2:e155.CrossRef Quintavalle C, Brenca M, de Micco F, Fiore D, Romano S, Romano MF, et al. In vivo and in vitro assessment of pathways involved in contrast media-induced renal cells apoptosis. Cell Death Dis. 2011;2:e155.CrossRef
8.
go back to reference Linkermann A, Bräsen JH, Darding M, Jin MK, Sanz AB, Heller JO, et al. Two independent pathways of regulated necrosis mediate ischemia-reperfusion injury. Proc Natl Acad Sci USA. 2013;110:12024–9.CrossRef Linkermann A, Bräsen JH, Darding M, Jin MK, Sanz AB, Heller JO, et al. Two independent pathways of regulated necrosis mediate ischemia-reperfusion injury. Proc Natl Acad Sci USA. 2013;110:12024–9.CrossRef
9.
go back to reference Zhu Y, Cui H, Xia Y, Gan H. RIPK3-mediated necroptosis and apoptosis contributes to renal tubular cell progressive loss and chronic kidney disease progression in rats. PLoS ONE. 2016;11:e0156729.CrossRef Zhu Y, Cui H, Xia Y, Gan H. RIPK3-mediated necroptosis and apoptosis contributes to renal tubular cell progressive loss and chronic kidney disease progression in rats. PLoS ONE. 2016;11:e0156729.CrossRef
10.
go back to reference Seeliger E, Sendeski M, Rihal CS, Persson PB. Contrast-induced kidney injury: mechanisms, risk factors, and prevention. Eur Heart J. 2012;33:2007–15.CrossRef Seeliger E, Sendeski M, Rihal CS, Persson PB. Contrast-induced kidney injury: mechanisms, risk factors, and prevention. Eur Heart J. 2012;33:2007–15.CrossRef
11.
go back to reference Ogasawara M, Yano T, Tanno M, Abe K, Ishikawa S, Miki T, et al. Suppression of autophagic flux contributes to cardiomyocyte death by activation of necroptotic pathways. J Mol Cell Cardiol. 2017;108:203–13.CrossRef Ogasawara M, Yano T, Tanno M, Abe K, Ishikawa S, Miki T, et al. Suppression of autophagic flux contributes to cardiomyocyte death by activation of necroptotic pathways. J Mol Cell Cardiol. 2017;108:203–13.CrossRef
12.
go back to reference Abe K, Yano T, Tanno M, Miki T, Kuno A, Sato T, et al. mTORC1 inhibition attenuates necroptosis through RIP1 inhibition-mediated TFEB activation. Biochim Biophys Acta Mol Basis Dis. 2019;1865:165552.CrossRef Abe K, Yano T, Tanno M, Miki T, Kuno A, Sato T, et al. mTORC1 inhibition attenuates necroptosis through RIP1 inhibition-mediated TFEB activation. Biochim Biophys Acta Mol Basis Dis. 2019;1865:165552.CrossRef
13.
go back to reference Nishizawa K, Yano T, Tanno M, Miki T, Kuno A, Tobisawa T, et al. Chronic treatment with an erythropoietin receptor ligand prevents chronic kidney disease-induced enlargement of myocardial infarct size. Hypertension. 2016;68:697–706.CrossRef Nishizawa K, Yano T, Tanno M, Miki T, Kuno A, Tobisawa T, et al. Chronic treatment with an erythropoietin receptor ligand prevents chronic kidney disease-induced enlargement of myocardial infarct size. Hypertension. 2016;68:697–706.CrossRef
14.
go back to reference Agmon Y, Peleg H, Greenfeld Z, Rosen S, Brezis M. Nitric oxide and prostanoids protect the renal outer medulla from radiocontrast toxicity in the rat. J Clin Invest. 1994;94:1069–75.CrossRef Agmon Y, Peleg H, Greenfeld Z, Rosen S, Brezis M. Nitric oxide and prostanoids protect the renal outer medulla from radiocontrast toxicity in the rat. J Clin Invest. 1994;94:1069–75.CrossRef
15.
go back to reference Muratsubaki S, Kuno A, Tanno M, Miki T, Yano T, Sugawara H, et al. Suppressed autophagic response underlies augmentation of renal ischemia/reperfusion injury by type 2 diabetes. Sci Rep. 2017;7:5311.CrossRef Muratsubaki S, Kuno A, Tanno M, Miki T, Yano T, Sugawara H, et al. Suppressed autophagic response underlies augmentation of renal ischemia/reperfusion injury by type 2 diabetes. Sci Rep. 2017;7:5311.CrossRef
16.
go back to reference Kimura Y, Kuno A, Tanno M, Sato T, Ohno K, Shibata S, et al. Canagliflozin, a sodium–glucose cotransporter 2 inhibitor, normalizes renal susceptibility to type 1 cardiorenal syndrome through reduction of renal oxidative stress in diabetic rats. J Diabetes Investig. 2019;10:933–46.CrossRef Kimura Y, Kuno A, Tanno M, Sato T, Ohno K, Shibata S, et al. Canagliflozin, a sodium–glucose cotransporter 2 inhibitor, normalizes renal susceptibility to type 1 cardiorenal syndrome through reduction of renal oxidative stress in diabetic rats. J Diabetes Investig. 2019;10:933–46.CrossRef
17.
go back to reference Wang Y, Zhang H, Yang Z, Miao D, Zhang D. Rho kinase inhibitor, fasudil, attenuates contrast-induced acute kidney injury. Basic Clin Pharmacol Toxicol. 2018;122:278–87.CrossRef Wang Y, Zhang H, Yang Z, Miao D, Zhang D. Rho kinase inhibitor, fasudil, attenuates contrast-induced acute kidney injury. Basic Clin Pharmacol Toxicol. 2018;122:278–87.CrossRef
18.
go back to reference MacHado RA, Constantino LDS, Tomasi CD, Rojas HA, Vuolo FS, Vitto MF, et al. Sodium butyrate decreases the activation of NF-κB reducing inflammation and oxidative damage in the kidney of rats subjected to contrast-induced nephropathy. Nephrol Dial Transplant. 2012;27:3136–40.CrossRef MacHado RA, Constantino LDS, Tomasi CD, Rojas HA, Vuolo FS, Vitto MF, et al. Sodium butyrate decreases the activation of NF-κB reducing inflammation and oxidative damage in the kidney of rats subjected to contrast-induced nephropathy. Nephrol Dial Transplant. 2012;27:3136–40.CrossRef
19.
go back to reference Reimer KA, Ganote CE, Jennings RB. Alterations in renal cortex following ischemic injury. 3. Ultrastructure of proximal tubules after ischemia or autolysis. Lab Invest. 1972;26:347–63.PubMed Reimer KA, Ganote CE, Jennings RB. Alterations in renal cortex following ischemic injury. 3. Ultrastructure of proximal tubules after ischemia or autolysis. Lab Invest. 1972;26:347–63.PubMed
20.
go back to reference Glaumann B, Glaumann H, Berezesky IK, Trump BF. Studies on the pathogenesis of ischemic cell injury II Morphological changes of the pars convoluta (P1 and P2) of the proximal tubule of the rat kidney made ischemic in vivo. Virchows Arch B Cell Pathol. 1975;19:281–302.PubMed Glaumann B, Glaumann H, Berezesky IK, Trump BF. Studies on the pathogenesis of ischemic cell injury II Morphological changes of the pars convoluta (P1 and P2) of the proximal tubule of the rat kidney made ischemic in vivo. Virchows Arch B Cell Pathol. 1975;19:281–302.PubMed
21.
go back to reference Glaumann B, Glaumann H, Trump BF. Studies of cellular recovery from injury. III. Ultrastructural studies on the recovery of the pars recta of the proximal tubule (P3 segment) of the rat kidney from temporary ischemia. Virchows Arch B Cell Pathol. 1977;25:281–308.PubMed Glaumann B, Glaumann H, Trump BF. Studies of cellular recovery from injury. III. Ultrastructural studies on the recovery of the pars recta of the proximal tubule (P3 segment) of the rat kidney from temporary ischemia. Virchows Arch B Cell Pathol. 1977;25:281–308.PubMed
22.
go back to reference Linkermann A, Heller JO, Prókai Á, Weinberg JM, de Zen F, Himmerkus N, et al. The RIP1-kinase inhibitor Necrostatin-1 prevents osmotic nephrosis and contrast-induced AKI in mice. J Am Soc Nephrol. 2013;24:1545–57.CrossRef Linkermann A, Heller JO, Prókai Á, Weinberg JM, de Zen F, Himmerkus N, et al. The RIP1-kinase inhibitor Necrostatin-1 prevents osmotic nephrosis and contrast-induced AKI in mice. J Am Soc Nephrol. 2013;24:1545–57.CrossRef
23.
go back to reference Dikic I, Elazar Z. Mechanism and medical implications of mammalian autophagy. Nat Rev Mol Cell Biol. 2018;19:349–64.CrossRef Dikic I, Elazar Z. Mechanism and medical implications of mammalian autophagy. Nat Rev Mol Cell Biol. 2018;19:349–64.CrossRef
24.
go back to reference Lei R, Zhao F, Tang CY, Luo M, Yang SK, Cheng W, et al. Mitophagy plays a protective role in iodinated contrast-induced acute renal tubular epithelial cells injury. Cell Physiol Biochem. 2018;46:975–85.CrossRef Lei R, Zhao F, Tang CY, Luo M, Yang SK, Cheng W, et al. Mitophagy plays a protective role in iodinated contrast-induced acute renal tubular epithelial cells injury. Cell Physiol Biochem. 2018;46:975–85.CrossRef
25.
go back to reference Gong X, Duan Y, Zheng J, Ye Z, Hei TK. Tetramethylpyrazine prevents contrast-induced nephropathy via modulating tubular cell mitophagy and suppressing mitochondrial fragmentation, CCL2/CCR2-mediated inflammation, and intestinal injury. Oxid Med Cell Longev. 2019;2019:7096912.PubMedPubMedCentral Gong X, Duan Y, Zheng J, Ye Z, Hei TK. Tetramethylpyrazine prevents contrast-induced nephropathy via modulating tubular cell mitophagy and suppressing mitochondrial fragmentation, CCL2/CCR2-mediated inflammation, and intestinal injury. Oxid Med Cell Longev. 2019;2019:7096912.PubMedPubMedCentral
26.
go back to reference Mulay SR, Linkermann A, Anders HJ. Necroinflammation in kidney disease. J Am Soc Nephrol. 2016;27:27–39.CrossRef Mulay SR, Linkermann A, Anders HJ. Necroinflammation in kidney disease. J Am Soc Nephrol. 2016;27:27–39.CrossRef
Metadata
Title
Involvement of necroptosis in contrast-induced nephropathy in a rat CKD model
Authors
Satoru Shibata
Norihito Moniwa
Atsushi Kuno
Ayumu Kimura
Wataru Ohwada
Hirohito Sugawara
Yufu Gocho
Marenao Tanaka
Toshiyuki Yano
Masato Furuhashi
Masaya Tanno
Takayuki Miki
Tetsuji Miura
Publication date
01-07-2021
Publisher
Springer Singapore
Published in
Clinical and Experimental Nephrology / Issue 7/2021
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-021-02048-1

Other articles of this Issue 7/2021

Clinical and Experimental Nephrology 7/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.